ANTIPHOSPHOLIPID SYNDROME
https://doi.org/10.51523/2708-6011.2017-14-4-1
Abstract
Antiphospholipid syndrome is autoimmune acquired thrombophilia associated with the formation of antibodies to phospholipids, which is manifested by recurrent venous or arterial thrombosis and/or pathology of pregnancy. Antiphospholipid antibodies are a heterogeneous group of autoantibodies interacting with phospholipids, which are components of cell membranes and phospholipid-binding proteins of blood plasma. Antiphospholipid syndrome can affect vessels of any caliber and localization, with thrombosis accompanied by no morphological signs of inflammation in the wall of the vessel. Obstetrical pathology is manifested by loss of the fetus, which can occur at any time of pregnancy, as well as other complications of pregnancy, such as preeclampsia and placental insufficiency. Based on the classification criteria, antiphospholipid syndrome is diagnosed if one of the clinical criteria (thrombosis or pregnancy complication) and one of the laboratory criteria including the lupus anticoagulant, antibodies to cardiolipin or β2-glycoprotein I, are revealed. The main tactic of the treatment of patients with antiphospholipid syndrome is to prevent thrombosis. For this purpose, the traditional therapy with anticoagulants and antiaggregants is applied. In addition, new medicines are being developed and evaluated
About the Author
E. V. Makarenko
Vitebsk State Order of Peoples` Friendship Medical University
Belarus
Belarus
References
1. The antiphospholipid syndrome: from pathophysiology to treatment / S. Negrini [et al.]// Clin. Exp. Med.-2017. -Vol. 17, № 3. -Р. 257-267.
2. Arachchillage, D.R.J.Pathogenesis and management of antiphospholipid syndrome / D. R. J. Arachchillage, M. Laffan // Br. J. Haematol.- 2017. -Vol. 178, № 2. - Р. 181-195.
3. Gómez-Puerta, J.A.Diagnosis and classification of the antiphospholipid syndrome / J. A. Gómez-Puerta, R. Cervera // J. Autoimmun.- 2014. -Vol. 48-49. -Р. 20-25.
4. Cervera, R. Antiphospholipid syndrome /R. Cervera // Thromb. Res.- 2017.-Vol. 151, Suppl. 1. -P. 43-47.
5. Antiphospholipid syndrome / M. Khamashta [et al.] // Best Pract. Res. Clin. Rheumatol.- 2016. -Vol. 30, №1.-Р. 133-148.
6. Hughes, G. R. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant / G. R. Hughes // Br. Med. J. (Clin Res Ed). - 1983. -Vol. 287, № 6399. -Р. 1088-1089.
7. Rodriguez-Pintó, I.Catastrophic antiphospholipid syndrome: The current managementapproach / I. Rodriguez-Pintó, G. Espinosa, R. Cervera // Best Pract. Res. Clin. Rheumatol.- 2016. -Vol. 30, № 2. -Р. 239-249.
8. Hughes, G. R. Seronegative antiphospholipid syndrome / G. R. Hughes, M. A. Khamashta // Ann. Rheum. Dis. - 2003. - Vol. 62, № 12. -Р. 1127.
9. Biggioggero, M. The geoepidemiology of the antiphospholipid antibody syndrome / M. Biggioggero, P. L. Meroni // Autoimmun. Rev. - 2010. - Vol. 9, № 5. - P. 299-304.
10. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a criticalreview of the literature / L. Andreoli [et al.] // Arthritis Care Res. (Hoboken). - 2013. - Vol. 65, № 11. -Р. 1869-1873.
11. Rai, R. Association of anti-phospholipid antibodies with connective tissue diseases / R. Rai, T. Swetha // Indian Dermatol. Online J. - 2015. - Vol. 6, № 2. -Р. 89-91.
12. Presence of antiphospholipid antibodies as a risk factor for thrombotic events in patients with connective tissue diseases and idiopathic thrombocytopenic purpura / K. Habe [et al.] // Intern. Med. - 2016. - Vol. 55, № 6. -Р. 589-595.
13. Sene, D. Antiphospholipid antibodies, antiphospholipid syndrome and viral infections / D. Sene, J. C. Piette, P. Cacoub // Rev. Med. Intern. - 2009. - Vol. 30, № 2. -Р. 135-141.
14. Antiphospholipid syndrome: an update / M. Merashli [et al.] // Eur. J. Clin. Investig. - 2015. -Vol. 45, № 6. -Р. 653-662.
15. Antiphospholipid syndrome / G. Ruiz-Irastorza [et al.] // Lancet. - 2010. -Vol. 376, № 9751. -Р. 1498-1509.
16. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) / S. Miyakis [et al.] // J. Thromb. Haemost. - 2006. -Vol. 4, № 2. -Р. 295-306.
17. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients / R. Cervera [et al.] // Arthritis Rheum. - 2002. -Vol. 46, № 4. -Р. 1019-1027.
18. Antiphospholipid Syndrome: Current Research Highlights and Clinical Insights / D. Erkan [et al.] // Springer-Verlag GmbH. - 2017. - 371 р.
19. GAPSS: the Global Anti-Phospholipid Syndrome Score / S. Sciascia[et al.] // Rheumatology (Oxford).- 2013. -Vol. 52, № 8. -Р. 1397-1403.
20. th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends / D. Erkan [et al.] // Autoimmun. Rev. - 2014. -Vol. 13, № 6. -Р. 685-696.
Review
For citations:
Makarenko E.V. ANTIPHOSPHOLIPID SYNDROME. Health and Ecology Issues. 2017;(4):4-11. (In Russ.) https://doi.org/10.51523/2708-6011.2017-14-4-1
Views: 573
Email this article 